Study: Diabetes Drug May Cut Risk of Alzheimer’s and Parkinson’s by 20%
SGLT2 inhibitors, a class of diabetes drugs, may reduce the risk of Alzheimer’s, vascular dementia, and Parkinson’s disease, according to a large study. Results showed a 20% to 30% lower risk for these conditions,
These Diabetes Drugs Could Help Lower Your Risk of Dementia, Parkinson’s
According to a new study, certain diabetes medications may significantly reduce this risk. These drugs, called gliflozins or SGLT2 inhibitors, stop the kidneys from reabsorbing too much blood glucose to improve blood sugar levels.
Some Diabetes Drugs May Protect Against Dementia and Parkinson's
Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 diabetes.
SGLT2 inhibitors reduce dementia, Parkinson’s disease risk: study
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of diabetes drugs also known as gliflozins, could lower the risk for dementia and Parkinson’s disease, a new study finds.
Diabetes drugs may protect against dementia
New research shows diabetes drugs may significantly reduce the risk of dementia, Alzheimer's, and Parkinson’s disease.
Some Diabetes Meds Could Lower Odds for Dementia, Parkinson's
A specific class of diabetes drug appears to lower people’s risk for dementia and Parkinson’s disease, a new study shows. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, also known as gliflozins, lower blood sugar by prompting the kidneys to filter sugar out of the bloodstream and excrete it in urine,
Type 2 drugs could lower dementia, Parkinson's disease risk
Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk of dementia, overall, and of Alzheimer's disease and Parkinson's, in particular.
Some diabetes drugs tied to lower risk of dementia, Parkinson's disease
A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a new study.
Neurology Advisor9h
SGLT2 Inhibitors, Dulaglutide Associated With Comparable Dementia Risk
SGLT2 inhibitors and dulaglutide are associated with comparable risk for dementia; however, it is uncertain whether these findings generalize to newer GLP-1 RAs.
How to manage heart and stroke risks before, during and after non-heart surgery
For people having surgery unrelated to their hearts, new guidelines detail how to manage heart and stroke risks before, ...
GlobalData on MSN24d
Diabetes duration has minimal impact on SGLT2 inhibitor efficacy, as per new analysis
A meta-analysis has demonstrated consistent efficacy in heart failure outcomes with SGLT2 inhibitors regardless of disease ...
Renal & Urology News1d
GLP-1 Receptor Agonists vs SGLT2 Inhibitors and Kidney, Heart Outcomes in T2D
In patients with type 2 diabetes, GLP-1 receptor agonists and SGLT2 inhibitors have similar kidney and cardiovascular outcomes. Similar kidney and cardiovascular outcomes are found with ...
Medscape11d
SGLT2 Inhibitor Reduces Risk for Neurodegenerative Diseases in T2D
"This was the largest nationwide population-based longitudinal cohort study to investigate the association between the use of ...
Daily13d
Study Reveals Significant Care Gap in SGLT2 Inhibitor Use for Diabetes and HF, Despite Real-World Benefits
Recent study highlights a significant care gap due to the underuse of SGLT2 inhibitors, despite their benefits. Canada: A ...